Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 5, 2007, Pages 658-666

  Mangili, G ^a   Picchio, M ^a   Sironi, S ^b,c   Vigano R ^a   Rabaiotti, E ^a   Bornaghi, D ^a   Bettinardi, V ^a   Crivellaro, C ^b   Messa, C ^b,c,d   Fazio, F ^a,b,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Clinical management; FDG; Ovarian cancer; PET CT; Single session staging procedure

Indexed keywords

ANTINEOPLASTIC AGENT; DIATRIZOATE; FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM; IOHEXOL; PLATINUM DERIVATIVE;

ABDOMINAL RADIOGRAPHY; ABDOMINAL SCINTISCANNING; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC APPROACH ROUTE; FEMALE; FOLLOW UP; HUMAN; OVARY CANCER; RETROSPECTIVE STUDY; TREATMENT PLANNING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34247575293     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0306-0     Document Type: Article

References (34)

1. Greenlee RT, Hill Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Ries LAG, Miller BA, Hankey BF. SEER cancer statistics review, 1973-1991. National Cancer Institute. NIH Publ. 1997;94:2789.
3. Topuz E, Aydiner A, Saip P, Eralp Y, Tas F, Salihoglu Y, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol. 2000;21:599-602.
4. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-Fluorine]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
5. Reske SN, Kotzerke J. FDG-PET for clinical use. Eur J Nucl Med 2001;28:1707-23.
6. 18F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med. 2003;47:77-84.
7. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol. 2001;176:1449-54.
8. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshkawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797-803.
9. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79.
10. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-81.
11. Casey J. Colonography and tumor staging during single-session PET/CT. Nature Clinical Practice Gastroenterology Hepatology 2006;3:184-5.
12. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167-75.
13. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233:433-40.
14. Kurtz AB, Tsimikas JV, Tempany CM, Hamper U, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis. Report of the Radiology Diagnostic Oncology Group. Radiology 1999;212:19-27.
15. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities - report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761-7.
16. Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761-7.
17. 18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000;126:560-74.
18. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17-21.
19. Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 2003;55:130-4.
20. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDGPET for management of cervical and ovarian cancer. Gynaecol Oncol 2005;97:183-91.
21. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-24.
22. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-89.
23. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002;43:752-6.
24. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 1999;2:63-70.
25. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(Suppl 5):1-93.
26. Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 2004;22:4147-56.
27. Pepe G, Rossetti C, Sironi S, Landoni C, Gianolli L, Pastorino U, et al. Patients with known or suspected lung cancer: evaluation of clinical management changes due to FDG PET study. Nucl Med Commun 2005;26:831-7.
28. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-smallcell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
29. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer. Thorax 2003;58:47-51.
30. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001;19:111-8.
31. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
32. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93.
33. 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001;42:586-90.
34. Ruiz-Hernandez G, Delgado-Bolton RC, Fernandez-Perez C, Lapena L, Jimenez-Vicioso A, Perez-Castejon MJ, et al. Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer. Rev Esp Med Nucl 2005;24:113-26.